Association between patient-reported outcomes and pathological response in neoadjuvant chemoimmunotherapy-a post hoc analysis of the TD-FOREKNOW trial [0.03%]
新辅助化疗免疫治疗的患者报告结果与病理缓解之间的关联：TD-FOREKNOW试验的事后分析
Bengang Hui,Na Zhang,Jiangnan Duan et al.
Bengang Hui et al.
Background: Neoadjuvant chemoimmunotherapy improves pathological outcomes and survival in resectable non-small cell lung cancer (NSCLC), but its effect on quality of life and the association between pathological response ...
Precision medicine in the first-line treatment of EGFR-mutated non-small cell lung cancer: moving beyond "one-size-fits-all" [0.03%]
EGFR突变非小细胞肺癌一线治疗的精准医学：超越“一刀切”模式
Hiroaki Ikushima,Hidenori Kage
Hiroaki Ikushima
Lung cancer associated with cystic airspaces in the perioperative immunotherapy era: radiologic and pathologic pitfalls, surgical extent, and management implications [0.03%]
免疫治疗时代的肺手术前后囊性含气腔隙与肺癌：影像学和病理学陷阱、外科切除范围及管理意义
Xue He,Qi Liu,Weijia Zeng et al.
Xue He et al.
With expanded use of screening and the rise of perioperative immunotherapy, early-stage non-small cell lung cancer management increasingly hinges on precise radiologic and pathologic staging. Lung cancer associated with cystic airspaces (LC...
Gender disparities in the overall survival of patients with minimally invasive squamous cell carcinoma of the lung: a retrospective analysis of the Surveillance, Epidemiology, and End Results Program database [0.03%]
基于SEER数据库的肺微创手术患者生存结局性别差异的回顾性分析研究
Yucheng Ma,Jiayue Ye,Jiacong Liu et al.
Yucheng Ma et al.
Background: In this study, we developed the concept of "minimally invasive lung squamous cell carcinoma" (LUSC), analyzed gender disparities in the overall survival (OS) of patients with this condition, and constructed a ...
Targeted therapy for stage IA non-small cell lung cancer with EGFR mutations: a scoping review [0.03%]
针对EGFR突变ⅠA期非小细胞肺癌患者靶向治疗的缩略综述
Yafei Xie,Liang Xia,Zhenyi Niu et al.
Yafei Xie et al.
Background: Patients with stage IA epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) also face recurrence risk, yet whether targeted therapy should be performed remains controver...
TROP2 expression as a prognostic predictor for osimertinib in patients with EGFR-mutant non-small cell lung cancer [0.03%]
TROP2表达量作为EGFR突变型非小细胞肺癌患者奥希替尼预后预测标志物的研究
Naohito Hashimoto,Kyoichi Kaira,Hisao Imai et al.
Naohito Hashimoto et al.
Background: Osimertinib is the standard first-line treatment for epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC); however, clinical outcomes vary widely even among patients receiving uni...
Consolidative thoracic radiotherapy after first-line chemoimmunotherapy in extensive-stage small-cell lung cancer: a multicenter retrospective study [0.03%]
广泛期小细胞肺癌一线化免疫治疗后的胸部巩固放疗：一项多中心回顾性研究
Shengxin Zhang,Nan Lin,Xiaojuan Gu et al.
Shengxin Zhang et al.
Background: While consolidative thoracic radiotherapy (cTRT) is standard after chemotherapy for extensive-stage small-cell lung cancer (ES-SCLC), its role in the immunotherapy era remains unclear, and this study provides ...
Impact of effective dose to immune cells (EDIC) on survival in limited-stage small cell lung cancer treated with radiotherapy and immunotherapy [0.03%]
有效免疫细胞剂量（EDIC）对局限期小细胞肺癌放疗联合免疫治疗患者生存影响的研究
Mengqian Jiang,Yuantao Qi,Zihong Zhu et al.
Mengqian Jiang et al.
Background: Concurrent chemoradiotherapy-immunotherapy is promising for limited-stage small cell lung cancer (LS-SCLC), but biomarkers integrating local and systemic immunity are needed. This study evaluates the prognosti...
Real-world effectiveness and safety of adebrelimab as first-line treatment in patients with extensive-stage small cell lung cancer [0.03%]
Adebrelimab作为广泛期小细胞肺癌一线治疗的疗效和安全性的真实世界研究
Tangfeng Lv,Bi Chen,Wei Chen et al.
Tangfeng Lv et al.
Background: Extensive-stage small cell lung cancer (ES-SCLC) is a highly aggressive malignancy. Although immune checkpoint inhibitors (ICIs) combined with chemotherapy have become standard first-line therapy, real-world e...
Timing of definitive pleural intervention within systemic anticancer therapy in malignant pleural effusion from high-response lung cancers: a retrospective single-center cohort study [0.03%]
晚期高反应性肺癌患者恶性胸腔积液全身治疗与胸膜干预的时机选择——单中心回顾性队列研究
Ana Pardessus Otero,Sergio Martínez-Recio,Albert Rafecas-Codern et al.
Ana Pardessus Otero et al.
Background: Malignant pleural effusion (MPE) is a common and serious complication of advanced lung cancer. Although guidelines recommend early definitive intervention, the optimal timing of talc pleurodesis-based definiti...